Today’s Hot List: IAC/InterActiveCorp (NASDAQ:IACI), Barclays (NYSE:BCS), Systemax (NYSE:SYX), KVH Industries Inc. (NASDAQ:KVHI), Acura Pharmaceuticals, Inc. (NASDAQ:ACUR)

Maxim Group started coverage on shares of IAC/InterActiveCorp (NASDAQ:IACI) in a research report released on Thursday morning. IAC/InterActiveCorp (NASDAQ:IACI) belongs to Technology sector. Its net profit margin is 6.40% and weekly performance is 5.80%. On last trading day company shares ended up $68.38. IAC/InterActiveCorp (NASDAQ:IACI) distance from 50-day simple moving average (SMA50) is 2.34%.

Espirito Santo Investment Bank Research restated their buy rating on shares of Barclays (NYSE:BCS) in a report released on Wednesday July 30. Barclays PLC (ADR) (NYSE:BCS) shares moved up 1.43% in last trading session and ended the day at $14.86. BCS return on assets is 0.10%. Barclays PLC (ADR) (NYSE:BCS) quarterly performance is -7.64%.

Systemax (NYSE:SYX) released its earnings data on Tuesday. The company reported $0.01 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.02) by $0.03.On 18 August, Systemax Inc. (NYSE:SYX) shares moved up 5.07% and was closed at $14.71. SYX EPS growth in last 5 year was -23.20%. Systemax Inc. (NYSE:SYX) year to date (YTD) performance is 30.76%.

On July 30, 2014  KVH Industries, Inc., (Nasdaq: KVHI) today reported financial results for the second quarter ended June 30, 2014. The company reported second quarter revenue of $40.9 million, net income on a generally accepted accounting principles (GAAP) basis of $0.1 million or $0.00 per diluted share, and non-GAAP net income of $0.8 million or $0.05 per diluted share. KVH Industries Inc. (NASDAQ:KVHI) ended the last trading day at $12.60. Company weekly volatility is calculated as 2.08%and price to cash ratio as 3.68. KVH Industries Inc. (NASDAQ:KVHI) showed a weekly performance of 0.16%.

On August 15,2014 Acura Pharmaceuticals (NASDAQ: ACUR) preliminary discussions from a meeting held with the U.S. Food and Drug Administration (FDA) regarding the development pathway for Acura’s AVERSION hydrocodone with acetaminophen tablet development candidate, which is intended to provide abuse-deterrent features to address abuse by nasal snorting and injection. In a May 2014 letter to Acura, FDA questioned the relevance of abuse of hydrocodone with acetaminophen products by nasal snorting after reviewing clinical and epidemiology data submitted by Acura. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) shares remains unchanged in last trading session and ended the day on $0.89. ACUR Gross Margin is 0.00% and its return on assets is -57.00%. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) quarterly performance is -27.05%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone